Found 162 articles for: "infliximab"
Dermatologists' Perspectives on Biosimilars
April 2024 | Volume 23 | Issue 4 | Features | 277 | Copyright © April 2024
Background: Biosimilars are biologic agents the Food and Drug Administration (FDA) has deemed to have no clinical difference from their reference biologics. In dermatology, biosi...
Read MoreBlood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis
February 2024 | Volume 23 | Issue 2 | Original Article | 74 | Copyright © February 2024
Early response to treatment with biologics, defined as Psoriasis Area and Severity Index (PASI) of 2 or less six months after initiation of therapy, seems to be associated with more stable psoria...
Read MoreA Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib
February 2024 | Volume 23 | Issue 2 | Case Reports | e60 | Copyright © February 2024
Tumor necrosis factor-alpha inhibitors (TNF-i) are commonly used to treat immune-mediated diseases such as psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease (IBD), spondyloarthriti...
Read MoreOff-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases
December 2023 | Volume 22 | Issue 12 | Original Article | 1183 | Copyright © December 2023
Dysregulation of Janus kinase (JAK) pathways from uncontrolled cytokine signaling comprises the pathological basis for many complex inflammatory cutaneous disorders. Oral JAK inhibitors, upadacit...
Read MoreMultiple Halo Nevi Induced by Intense Sun Exposure
December 2023 | Volume 22 | Issue 12 | Case Reports | e31 | Copyright © December 2023
We present the case of a 38-year-old male who reported to our practice with multiple newly developed halos around 26 existing nevi on his trunk. The halo nevi developed after the patient, who liv...
Read MoreINDIVIDUAL ARTICLE: Real-World Evidence on the Use of Calcipotriene and Betamethasone Dipropionate Aerosol Foam 0.005%/0.064% in the Treatment of Psoriasis: A Review of Investigator-Initiated Studies Around the Globe
September 2023 | Volume 22 | Issue 9 | Supplement Individual Articles | SF378719s5 | Copyright © September 2023
Topical medications are commonly used to manage mild-to-moderate psoriasis and serve as adjunct therapies used in combination with phototherapy and systemic treatments. Fixed-dose calcipotriene (Cal) ...
Read MoreDapsone to Treat Moderate-to-Severe Hidradenitis Suppurativa: A Retrospective Case-Series
November 2023 | Volume 22 | Issue 11 | Features | e12 | Copyright © November 2023
Background: Management of hidradenitis suppurativa (HS) is challenging since no single treatment provides consistently effective results, leaving patients with frequent relapses....
Read MoreINDIVIDUAL ARTICLE: Real-World Evidence on the Use of Calcipotriene and Betamethasone Dipropionate Aerosol Foam 0.005%/0.064% in the Treatment of Psoriasis: A Review of Investigator-Initiated Studies Around the Globe
September 2023 | Volume 22 | Issue 9 | Department | SF378719s5 | Copyright © September 2023
Topical medications are commonly used to manage mild-to-moderate psoriasis and serve as adjunct therapies used in combination with phototherapy and systemic treatments. Fixed-dose calcipotriene (Cal) ...
Read MoreDiagnosis and Management of Pediatric Psoriasis: An Overview for Pediatricians
August 2023 | Volume 22 | Issue 8 | Original Article | 742 | Copyright © August 2023
Pediatric psoriasis (PsO) and its associated comorbidities carry physical and psychosocial burdens in children and adolescents, which can negatively impact quality of life. However, features dist...
Read MorePsoriasis and Skin Barrier Dysfunction: The Role of Gentle Cleansers and Moisturizers in Treating Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 773 | Copyright © August 2023
Background: Psoriasis is a chronic immune-mediated dermatologic disorder with multisystemic comorbidities, which is effectively treated with a range of prescription therapies. St...
Read MoreRethinking the Inflammatory Balance in Psoriasis and Atherosclerosis
August 2023 | Volume 22 | Issue 8 | Features | 832 | Copyright © August 2023
Guénin S, Kazemi A, Cline A, et al. Rethinking the inflammatory balance in psoriasis and atherosclerosis. J Drugs Dermatol. 2023;22(8):832-833. doi:10.36849/JDD.7082...
Read MoreCutaneous Sarcoidosis in Skin of Color
July 2023 | Volume 22 | Issue 7 | Features | 695 | Copyright © July 2023
Cutaneous sarcoidosis presents in 25% of all sarcoidosis cases. African American populations, particularly African American women, are more likely to develop the dermatologic manifestations of th...
Read MoreAnti-Tumor Necrosis Factor Alpha Therapeutic Drug Monitoring in Inflammatory Disease: A Systematic Review
May 2023 | Volume 22 | Issue 5 | Original Article | 445 | Copyright © May 2023
Background: Monoclonal antibodies encompass an increasingly important treatment for a variety of dermatologic conditions including hidradenitis suppurativa (HS). The high failure...
Read MoreImmune-Response Modifiers: Characteristics of High-Volume Prescribers
December 2022 | Volume 21 | Issue 12 | Original Article | 1283 | Copyright © December 2022
Background: Oral small molecules (OSM) and biologic immune response modifier drugs share some indications for use but have a different side effect profiles. As such, certain providers...
Read MoreNovel Regimen of IL-17A Inhibitor Secukinumab for the Remission of Severe Hidradenitis Suppurativa: Case Report
December 2022 | Volume 21 | Issue 12 | Case Reports | 1358 | Copyright © December 2022
Hidradenitis suppurativa (HS) is a morbid, recurrent skin condition that presents a major challenge to clinical therapy. Investigation into the pathogenesis of HS has implicated local and systemic pro...
Read MoreConcurrent Interstitial Granulomatous Dermatitis and TNF-α Antagonist-Induced Lupus Syndrome Secondary to Adalimumab for Crohn's Disease
November 2022 | Volume 21 | Issue 11 | Case Reports | 1256 | Copyright © November 2022
Tumor necrosis factor (TNF) antagonists have revolutionized management for various autoimmune and inflammatory conditions, including rheumatoid arthritis (RA), inflammatory bowel disease, hidradenitis...
Read MorePersistence With Biologic Treatments in Psoriasis: A Structured Literature Review of Studies Using Administrative Database and Clinical Registry Data
August 2022 | Volume 21 | Issue 8 | Original Article | 881 | Copyright © August 2022
Background: Psoriasis is a chronic, autoimmune-mediated inflammatory disorder. Drug persistence is a composite measure of effectiveness, safety, and treatment satisfaction, often esti...
Read MoreThe Incidence and Risk of Respiratory Tract Infections in Patients Using Biologics for Hidradenitis Suppurativa: A Systematic Review and Meta-analysis
August 2022 | Volume 21 | Issue 8 | Original Article | 819 | Copyright © August 2022
Background: Patients treated with biological therapy for hidradenitis suppurativa (HS) are at an increased risk of infectious complications. However, it is unclear whether these patie...
Read MoreNew Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 826 | Copyright © August 2022
Psoriasis is known to have no definitive cure, which is in common with other inflammatory disorders. Various treatment options are available, and they help in decreasing the disease activity and impro...
Read MoreTreatment of Scalp Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 833 | Copyright © August 2022
Scalp involvement is seen in a majority of individuals with psoriasis, a chronic autoimmune skin disease with variable phenotypes. Occasionally, isolated scalp involvement is observed; and this causes...
Read MoreMedia and other results for: "infliximab"